NCT07138729 Research on the Application of 99mTc-TCR-FAPI SPECT Imaging in Rheumatoid Arthritis
| NCT ID | NCT07138729 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Luo Yaping |
| Condition | Rheumatoid Arthritis (RA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-05-10 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-05-10 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study proposes to evaluate 99mTc-CTR-FAPI SPECT imaging as a cost-effective, low-radiation, and widely accessible alternative to 68Ga-FAPI PET/CT for assessing synovial lesions in RA patients, aiming to validate its diagnostic consistency with both PET/CT and physical examinations while correlating imaging findings with clinical disease activity metrics to establish a practical tool for long-term RA monitoring.
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-75 years old; 2. Meet the classification criteria for rheumatoid arthritis of the American College of Rheumatology/European Union for Rheumatology in 2010; 3. The highest disease activity in clinical practice (CDAI or SDAI score Exclusion Criteria: 1. Patients with other autoimmune diseases; 2. Patients with concurrent tumors; 3. Women who are pregnant or planning to become pregnant, women in the preconception period, pregnant and lactating women, and women with child-rearing plans during the study period; Subjects of childbearing age need to take effective contraceptive measures during the research process; 4. Active infection 5. Suffering from claustrophobia or other mental disorders, with poor compliance resulting in inability to cooperate with this researcher; (6) Situations where other researchers consider it inappropriate to participate in this clinical trial.
Contact & Investigator
Yaping LUO
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT07138729 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Rheumatoid Arthritis (RA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07138729 currently recruiting?
Yes, NCT07138729 is actively recruiting participants. Contact the research team at luoyaping@live.com for enrollment information.
Where is the NCT07138729 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07138729 clinical trial?
NCT07138729 is sponsored by Luo Yaping. The principal investigator is Yaping LUO at Peking Union Medical College Hospital. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.